logo
logo

Capital Rx Closes $106M Series C To Improve Prescription Management And Healthcare Infrastructure

Jun 13, 2022•over 3 years ago

Amount Raised

$106 Million

Round Type

series c

Description

Capital Rx, a health technology company changing the way prescription drugs are priced and patients are serviced, today announced the close of its $106M Series C funding led by B Capital, with participation from General Catalyst and existing investors, Transformation Capital and Edison Partners. With the closing, Capital Rx increases overall funding to $175M and welcomes Dr. Robert Mittendorff, General Partner and Head of Healthcare at B Capital, to the Company's Board of Directors. B Capital Principal Nick Whitehead and Holly Maloney, Managing Director at General Catalyst, will join as board observers.

Company Information

Company

Capital Rx

About

Leveraging modern architecture that collapses the silos of information between healthcare stakeholders, the platform improves pharmacy network management tools and allows for faster implementations of more highly customizable benefit designs to support the next generation of value-based contracts. "Capital Rx has the clearest vision we've seen in the market for how to transform the infrastructure of healthcare to enable better care at a lower cost," said Dr. Robert Mittendorff, General Partner at B Capital. Nick Whitehead continues, "Our thematic work in the PBM space has confirmed that Capital Rx has the most advanced tech stack and solution to power next generation PBMs."

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech